• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Hawkins, Robert E
    Daigneault, Luc
    Cowan, Richard A
    Griffiths, Richard W
    Panchal, Chandra
    Armstrong, Anne C
    Fenemore, Jackie
    Irvine, Alan
    Sereda, Kasia
    Dulude, Hélène
    Affiliation
    Medical Oncology Paterson Institute for Cancer Research, Christie Research Center, Manchester, UK.
    Issue Date
    2005-09
    
    Metadata
    Show full item record
    Abstract
    BACKGROUND: The safety, tolerability, and pharmacokinetic and preliminary efficacy of PCK3145 were determined in patients with metastatic hormone-refractory prostate cancer. PATIENTS AND METHODS: PCK3145 was administered in ascending doses of 5, 20, 40, and 80 mg/m2 3 times per week for 4 weeks to cohorts of 4 patients. Dose escalation was based on dose-limiting toxicity (DLT). Pharmacokinetic profiles, tumor burden, and tumor markers (including prostate-specific antigen [PSA] and matrix metalloproteinase-9 [MMP-9] levels) were assessed. Sixteen patients received PCK3145. The median age was 66 years, and the median PSA level was 232.5 microg/L. A total of 32 cycles of therapy were administered. RESULTS: The most common adverse events reported were pain and nausea. The only DLT was a grade 4 cardiac arrhythmia in a patient treated at the 80-mg/m2 dose level. Pharmacokinetic analysis using a 2-compartment model indicated that the mean area under the curve values increased as the dose range increased, and the mean elimination half-life ranged from 0.35 hours to 1.45 hours. The best tumor response was stable disease in 10 patients and progressive disease in 5 patients. No PSA responses were observed, but 1 patient showed a marked reduction in PSA of 41% at cycle 2. A substantial reduction in MMP-9 levels was observed in patients with baseline levels of MMP-9 > 100 microg/L. CONCLUSION: PCK3145 was safe and well tolerated at all doses. Efficacy observations were encouraging, and the biologic activity of PCK3145 in reducing MMP-9 level may suggest a potential role of this peptide in the regulation of metastatic tumor growth.
    Citation
    Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. 2005, 4 (2):91-9 Clin Prostate Cancer
    Journal
    Clinical Prostate Cancer
    URI
    http://hdl.handle.net/10541/76841
    PubMed ID
    16197609
    Type
    Article
    Language
    en
    ISSN
    1540-0352
    Collections
    All Christie Publications
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling.
    • Authors: Annabi B, Bouzeghrane M, Currie JC, Dulude H, Daigneault L, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R
    • Issue date: 2006 Apr
    • Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer.
    • Authors: Shukeir N, Garde S, Wu JJ, Panchal C, Rabbani SA
    • Issue date: 2005 Nov
    • A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia.
    • Authors: Shukeir N, Arakelian A, Chen G, Garde S, Ruiz M, Panchal C, Rabbani SA
    • Issue date: 2004 Aug 1
    • A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: implication in tumor angiogenesis.
    • Authors: Lamy S, Ruiz MT, Wisniewski J, Garde S, Rabbani SA, Panchal C, Wu JJ, Annabi B
    • Issue date: 2006 May 1
    • A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: implication in tumor metastasis.
    • Authors: Annabi B, Bouzeghrane M, Currie JC, Hawkins R, Dulude H, Daigneault L, Ruiz M, Wisniewski J, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R
    • Issue date: 2005
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.